U.S. Needs to Reform Discovery, Development, Delivery of Drugs
Friday, October 3, 2014
Source: Boston Herald
U.S. regulators need to guarantee rewards for innovation, promote wider data sharing while protecting privacy and improve the existing drug-development model, write Nobel Prize winner Phillip Sharp, Tufts Center for the Study of Drug Development Director Kenneth Kaitin and former FDA Commissioner Dr. Andrew von Eschenbach. Because Massachusetts is a leader in life sciences innovation, it is the right place to examine greater ways to incentivize innovative drugmakers for bringing greater value to patients, they write. The state can only maintain and expand its leadership in the life-sciences sector if the U.S. changes its process of discovering, developing and delivering better drugs to patients, they write.